The side effect (SE) profile for dapagliflozin in DAPA trial is very impressive and was not quite different from placebo in the control group when used on top of other GDMT.
Is the drug really as safe as placebo or is this effect due to very close monitoring and appropriate dosage adjustment in the trial pts?
I ask this question because the previous trials with DAPA have demonstrated various SE (most common being urogenital infections but then also euglycemic DKA as well as increased risk of amputations with use of canagliflozin etc)
Is this benign SE profile unique for this member (dapagliflozin) of SGLT2i, or is it due to close monitoring of trial pts? Does this hold true from your experience in clinical practice when you prescribe it to diabetics?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.